262 related articles for article (PubMed ID: 28629761)
21. Role of NKG2D in cytokine-induced killer cells against multiple myeloma cells.
Lu X; Zhu A; Cai X; Jia Z; Han W; Ma L; Zhou M; Qian K; Cen L; Chen B
Cancer Biol Ther; 2012 Jun; 13(8):623-9. PubMed ID: 22555808
[TBL] [Abstract][Full Text] [Related]
22. In vitro analysis of the proliferative capacity and cytotoxic effects of ex vivo induced natural killer cells, cytokine-induced killer cells, and gamma-delta T cells.
Niu C; Jin H; Li M; Xu J; Xu D; Hu J; He H; Li W; Cui J
BMC Immunol; 2015 Oct; 16():61. PubMed ID: 26458364
[TBL] [Abstract][Full Text] [Related]
23. Polysaccharides from Hedyotis diffusa enhance the antitumor activities of cytokine-induced killer cells.
Ma C; Wei Y; Liu Q; Xin Y; Cao G; Wang X; Yang P
Biomed Pharmacother; 2019 Sep; 117():109167. PubMed ID: 31387180
[TBL] [Abstract][Full Text] [Related]
24. Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation.
Sangiolo D; Mesiano G; Carnevale-Schianca F; Piacibello W; Aglietta M; Cignetti A
Expert Opin Biol Ther; 2009 Jul; 9(7):831-40. PubMed ID: 19463075
[TBL] [Abstract][Full Text] [Related]
25. CIK as therapeutic agents against tumors.
Introna M
J Autoimmun; 2017 Dec; 85():32-44. PubMed ID: 28679475
[TBL] [Abstract][Full Text] [Related]
26. Cancer Immunotherapy with Cytokine-Induced Killer Cells.
Mata-Molanes JJ; Sureda González M; Valenzuela Jiménez B; Martínez Navarro EM; Brugarolas Masllorens A
Target Oncol; 2017 Jun; 12(3):289-299. PubMed ID: 28474278
[TBL] [Abstract][Full Text] [Related]
27. In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity.
Nishimura R; Baker J; Beilhack A; Zeiser R; Olson JA; Sega EI; Karimi M; Negrin RS
Blood; 2008 Sep; 112(6):2563-74. PubMed ID: 18565854
[TBL] [Abstract][Full Text] [Related]
28. Dendritic Cells Therapy with Cytokine-Induced Killer Cells and Activated Cytotoxic T Cells Attenuated Th2 Bias Immune Response.
Li C; Zhu D; Zhao Y; Guo Q; Sun W; Li L; Gao D; Zhao P
Immunol Invest; 2020 Jul; 49(5):522-534. PubMed ID: 31793363
[TBL] [Abstract][Full Text] [Related]
29. CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma.
Giraudo L; Cattaneo G; Gammaitoni L; Iaia I; Donini C; Massa A; Centomo ML; Basiricò M; Vigna E; Pisacane A; Picciotto F; Berrino E; Marchiò C; Merlini A; Paruzzo L; Poletto S; Caravelli D; Biolato AM; Bortolot V; Landoni E; Ventin M; Ferrone CR; Aglietta M; Dotti G; Leuci V; Carnevale-Schianca F; Sangiolo D
J Exp Clin Cancer Res; 2023 Nov; 42(1):310. PubMed ID: 37993874
[TBL] [Abstract][Full Text] [Related]
30. Human interferon-alpha increases the cytotoxic effect of CD56(+) cord blood-derived cytokine-induced killer cells on human B-acute lymphoblastic leukemia cell lines.
Durrieu L; Gregoire-Gauthier J; Dieng MM; Fontaine F; le Deist F; Haddad E
Cytotherapy; 2012 Nov; 14(10):1245-57. PubMed ID: 22974386
[TBL] [Abstract][Full Text] [Related]
31. Co-Expansion of Cytokine-Induced Killer Cells and Vγ9Vδ2 T Cells for CAR T-Cell Therapy.
Du SH; Li Z; Chen C; Tan WK; Chi Z; Kwang TW; Xu XH; Wang S
PLoS One; 2016; 11(9):e0161820. PubMed ID: 27598655
[TBL] [Abstract][Full Text] [Related]
32. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS
Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871
[TBL] [Abstract][Full Text] [Related]
33. Ex vivo-activated MHC-unrestricted immune effectors for cancer adoptive immunotherapy.
Leuci V; Mesiano G; Gammaitoni L; Todorovic M; Giraudo L; Carnevale-Schianca F; Aglietta M; Sangiolo D
Anticancer Agents Med Chem; 2014 Feb; 14(2):211-22. PubMed ID: 24237224
[TBL] [Abstract][Full Text] [Related]
34. Thymoglobulin, interferon-γ and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures.
Bonanno G; Iudicone P; Mariotti A; Procoli A; Pandolfi A; Fioravanti D; Corallo M; Perillo A; Scambia G; Pierelli L; Rutella S
J Transl Med; 2010 Dec; 8():129. PubMed ID: 21138560
[TBL] [Abstract][Full Text] [Related]
35. Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models.
Shi S; Wang R; Chen Y; Song H; Chen L; Huang G
PLoS One; 2013; 8(6):e65757. PubMed ID: 23799045
[TBL] [Abstract][Full Text] [Related]
36. The CIK cells stimulated with combination of IL-2 and IL-15 provide an improved cytotoxic capacity against human lung adenocarcinoma.
Wei C; Wang W; Pang W; Meng M; Jiang L; Xue S; Xie Y; Li R; Hou Z
Tumour Biol; 2014 Mar; 35(3):1997-2007. PubMed ID: 24104501
[TBL] [Abstract][Full Text] [Related]
37. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers.
Sangiolo D; Martinuzzi E; Todorovic M; Vitaggio K; Vallario A; Jordaney N; Carnevale-Schianca F; Capaldi A; Geuna M; Casorzo L; Nash RA; Aglietta M; Cignetti A
Int Immunol; 2008 Jul; 20(7):841-8. PubMed ID: 18469328
[TBL] [Abstract][Full Text] [Related]
38. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
39. [Roles of NKG2D in cytokine-induced killer (CIK) against hematological malignant cells lines].
He JY; Jia ZX; Cai XH; Han WM; Xiao R; Ma LD; Lu XZ; Zhou M; Chen BA
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1380-4. PubMed ID: 24370015
[TBL] [Abstract][Full Text] [Related]
40. Bone marrow mesenchymal stem cells reduce the antitumor activity of cytokine-induced killer/natural killer cells in K562 NOD/SCID mice.
Li Y; Qu YH; Wu YF; Wang XP; Wei J; Huang WG; Zhou DH; Fang J; Huang K; Huang SL
Ann Hematol; 2011 Aug; 90(8):873-85. PubMed ID: 21234566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]